Prevalence and Associated Factors of Metabolic Bone Disease in Men with Type 2 Diabetes Mellitus

Author:

Kamaruzaman Hanis Rabeah1,Hatta Sharifah Faradila Wan Muhamad1,Sharif Nur Hidayati Mohd1,Ismail Zaliha2,Idorus Mohd Yusri3,Rahman Thuhairah Hasrah Abdul4,Razali Rafezah5,Ghani Rohana Abdul1

Affiliation:

1. Department of Internal Medicine, Faculty of Medicine, Hospital Al –Sultan Abdullah, UiTM Puncak Alam

2. Public Health Medicine, Faculty of Medicine, University Teknologi MARA

3. Institute of Medical Molecular Biotechnology, Faculty of Medicine, University Teknologi MARA

4. Chemical Pathologist, Faculty of Medicine, University Teknologi MARA

5. Department of Clinical Diagnostic Laboratory Hospital Al –Sultan Abdullah, UiTM Puncak Alam

Abstract

Abstract INTRODUCTION Postmenopausal women and people over the age of 70 are more likely to develop osteoporosis. It is recognized as significant comorbidity among those with type 2 diabetes mellitus (T2DM), and male fractures are on the rise with higher rates of mortality than women (37.5% vs 28.2% respectively). However, there is a scarcity of data linking T2DM and metabolic bone disease in men. OBJECTIVE Our study aimed to determine the prevalence of metabolic bone diseases, including osteoporosis and osteopenia, and the associated factors, bone turnover markers, and vitamin D in men with T2DM. METHOD This is a cross-sectional, single-center study in men above 50 years of age with T2DM, conducted from December 2021 to June 2022. Demographic data, baseline comorbidities, and biochemical profiles including urine albumin-creatinine ratio (UACR) was obtained. Bone turnover markers including C-terminal telopeptide of type I collagen (CTX) and bone-specific alkaline phosphates (bsALP) were measured. Osteoporosis and osteopenia were determined by Dual Energy X-ray Absorptiometry (DEXA). RESULT Total of 148 men with T2DM with a median age of 64 (IqR 11) years was recruited. The prevalence of metabolic bone disease in the study population was 20.3%. Multivariate analysis shows total bilirubin level [OR: 1.13 (95% CI: 1.050, 1.223) p<0.001], high intact parathyroid hormone (iPTH) level ≥6.9 pmol/L [OR 3.05 (95% CI: 1.141, 8.187), p=0.026] and use of dipeptidyl peptidase-4 inhibitor (DPP4i) [OR 0.274 (95% CI: 0.093, 0.809) p=0.01] are predictors of metabolic bone disease in the study population. CONCLUSION Metabolic bone disease affects about 1 in 5 men with T2DM patients, and its risk factors include increased total bilirubin and iPTH level. The use of DPP4i for the treatment of T2DM was shown to be somewhat protective against metabolic bone disease. There is a need to identify metabolic bone disease in men with T2DM so early intervention could be initiated to prevent fractures.

Publisher

Research Square Platform LLC

Reference41 articles.

1. Cundy T, Reid IR, Grey A, CHAPTER 31 - Metabolic bone disease, in Clinical Biochemistry: Metabolic and Clinical Aspects (Third Edition), W.J. Marshall, et al., Editors. 2014, Churchill Livingstone. p. 604–635.

2. The relationship between insulin resistance and osteoporosis in elderly male type 2 diabetes mellitus and diabetic nephropathy;Xia J;Ann Endocrinol (Paris),2012

3. The Asia-Pacific Regional Audit-Epidemiology, Costs, and Burden of Osteoporosis in India 2013: A report of International Osteoporosis Foundation;Mithal A;Indian J Endocrinol Metab,2014

4. Osteoporosis and osteopenia in the distal forearm predict all-cause mortality independent of grip strength: 22-year follow-up in the population-based Tromso Study;Hauger AV;Osteoporos Int,2018

5. Excess mortality following hip fracture: a systematic epidemiological review;Abrahamsen B;Osteoporos Int,2009

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3